Privia Health Group stock inched up 2.1% to US$22.45 after its Q2 print, a modest move for a company investors have punished over the past month with a slide of about 17%. The market’s first take looks cautious, yet the headline from this quarter is clear. Revenue reached US$632.6m and adjusted EBITDA climbed to US$37.4m, with management lifting full year guidance and pointing to improving margins. For anyone looking beyond today’s quote, the story now turns to whether those margins and cash generation can support a premium P/E and the richer long term growth case.

Love Privia Health Group's raised guidance and improving margin story but concerned about paying a premium P/E for it? Compare that setup with our screener of list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$632.63m vs. US$521.15m (up about 21.4%)
• Net Income, Excluding Extra Items (Q2 2026 vs. Q2 2025): US$9.05m vs. US$2.69m (up about 236.9%)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.07174 vs. US$0.02200 (up about 226.1%)
• Adjusted EBITDA (Q2 2026 vs. Q2 2025): US$37.4m vs. about US$29.0m (up 29%)

Prefer clean visuals instead of sifting through dense earnings tables and raw numbers? View the full picture for Privia Health Group in an easy dashboard that highlights valuation alongside other key metrics in our company report for Privia Health Group.

Privia’s Growth-Margin Flywheel Largely Delivers

Bulls argue Privia Health Group can compound value by growing attributed lives and providers while steadily lifting margins and cash conversion. Q2 goes a long way toward supporting that view. Implemented providers reached 5,644, up 10.1% year on year, and attributed lives climbed to 1.64m with broad based growth across commercial, Medicare and Medicaid. Practice collections of US$970m in the quarter and 13.4% growth in the first half show the value based network is scaling. The key milestone is profitability quality. Adjusted EBITDA grew faster than revenue and reached 28.3% of care margin, up 310 basis points year on year, moving closer to management’s 30 to 35% long term target. Management also raised 2026 guidance across practice collections, care margin, EBITDA and lives. For the bullish thesis, that is direct evidence that scale, technology and AI deployment are starting to translate into better unit economics.

Bear Concerns On Quality Of Profits Not Resolved

Bears worry that Privia’s growth comes with thin free cash flow, low returns on invested capital and execution risk in value based models. Q2 does not fully ease those concerns. Management still describes the business as requiring multi year build outs in new states such as New Jersey, with integration and provider density taking time. That keeps execution risk front and center. Cash conversion is flagged as 70 to 80% of full year adjusted EBITDA, but this depends on timely Medicare Shared Savings Program (MSSP, a U.S. Medicare value based payment model) settlements, which management warns could be delayed by CMS process changes. The company also remains exposed to payer behavior and mix shifts in Medicare Advantage and Medicaid. Recent insider selling around prior quarters, even if largely pre planned, sits against this backdrop and can reinforce questions about how quickly improving EBITDA margins will translate into durable, self funded free cash flow.

After multi year state build outs, payer mix shifts and insider selling, you may want independent eyes on hidden weaknesses. Review our risk analysis for Privia Health Group which shows 1 important warning sign.

Take Control Of Your Next Move

If Privia Health Group’s raised guidance and improving margin profile have your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch how the thesis develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key fundamental and earnings updates that matter for your holdings. For a longer term view on Privia Health Group and other stocks, tap into crowd insights through the Community and see how different investors are weighing the same risks and opportunities. This way you can surface potential catalysts or warning signs early and stay ahead of the market.

Seeking Alternatives Beyond Privia Health Group

Fresh stock ideas can move from quiet to flying once momentum builds. Scan these under the radar for now themes before the crowd catches on. Consider researching these areas.

• Spot potential breakout infrastructure plays by scanning 36 power grid technology and infrastructure stocks that could benefit as capital chases essential upgrades while they are still priced as if nothing has changed.
• Track where robotics demand may build next by reviewing 36 robotics and automation stocks curated for companies automating real world workflows before the story gets fully priced in.
• Zero in on crypto related stocks with real businesses behind them by using 20 cryptocurrency and blockchain stocks before momentum traders crowd into the same limited list.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.